Outcomes with As-Needed Ranibizumab after Initial Monthly Therapy
نویسندگان
چکیده
منابع مشابه
Individualized ranibizumab therapy strategies in year 3 after as-needed treatment for polypoidal choroidal vasculopathy
BACKGROUND To investigate the third-year results of ranibizumab monotherapy for polypoidal choroidal vasculopathy (PCV) in individualized treatment regimens based on the outcomes during 2 years. METHODS One hundred seventy-two consecutive eyes of 163 prospective treatment-naïve patients with PCV were treated with three monthly intravitreal ranibizumab injections followed by as-needed reinject...
متن کاملRisk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy
We report our experience with the use of intravitreal ranibizumab for the treatment of retinopathy of prematurity (ROP). A retrospective review was performed on 138 consecutive infants screened at a single centre over 18 months. Intravitreal ranibizumab was offered in selected cases requiring treatment, such as aggressive posterior ROP or poor mydriasis. 2 eyes of 1 infant received intravitreal...
متن کاملResults of 2 years of treatment with as-needed ranibizumab reinjection for polypoidal choroidal vasculopathy
PURPOSE To investigate the 2-year outcomes of three monthly intravitreal ranibizumab injections followed by as-needed reinjections to treat polypoidal choroidal vasculopathy (PCV). METHODS Seventy-five consecutive eyes with naïve symptomatic PCV with 2 years of follow-up after treatment were studied prospectively. RESULTS The mean (±SD) numbers of injections were 4.2±1.3 that included three...
متن کاملSwitch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
BACKGROUND To evaluate changes in central macular thickness (CMT) and visual outcome in patients with neovascular age-related macular degeneration (AMD) treated initially with bevacizumab and subsequently switched to either aflibercept or ranibizumab. METHODS Observational clinical study was performed. We measured the structural outcome (CMT on SD-OCT; μm) and the visual outcome (best correct...
متن کاملAdult-onset vitelliform detachment unresponsive to monthly intravitreal ranibizumab.
A 72-year-old woman with decreased visual acuity secondary to an adult-onset vitelliform detachment was treated with three monthly intravitreal injections of 0.5 mg of ranibizumab. Treatment response was monitored by visual acuity and by the eye-tracking feature of the Heidelberg Spectralis spectral domain optical coherence tomography (Heidelberg Engineering, Inc., Carlsbad, CA). There was no i...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Ophthalmology
سال: 2015
ISSN: 0161-6420
DOI: 10.1016/j.ophtha.2015.08.006